SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore is trending as traders closely monitor the legal and political battle over the Santa Ynez pipeline restart, with significant debate surrounding the Trump administration's efforts to invoke the Defense Production Act to bypass California's state regulatory restrictions. Community discussions are heavily focused on the high short interest and the potential for a major short squeeze, as investors weigh the company's federal support against ongoing local legal opposition.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is experiencing significant market attention and upward momentum following the announcement of a full notice to proceed on a 2.4 billion dollar AI data center power project. Investors are actively debating the company's long-term growth potential and the strategic significance of its partnership with Siemens Energy, while navigating noise from short-seller reports.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is currently trending as investors focus on its recent acquisition of Astria Therapeutics and look ahead to the upcoming earnings release and clinical data for the navenibart program at the AAAAI meeting. Community discussions are heavily centered on high institutional ownership levels, persistent short interest, and frustration regarding the stock's long-term performance despite consistent revenue growth from Orladeyo.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is seeing increased transaction volume following the recent integration of Evolution, which has fueled community speculation about the coin's long-term utility and potential for a breakout. Investors are actively discussing the broader resurgence of privacy-focused assets, with many highlighting the coin's low supply and recent development milestones as key drivers for their bullish outlook.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant volatility as investors debate the impact of the company's deepening financial ties with SpaceX and xAI, alongside ongoing concerns regarding the delayed production timeline of the highly anticipated Cybercab. The community is sharply divided, with bulls pointing toward the potential of future energy and robotics technology while vocal bears are heavily shorting the stock, citing management credibility issues and the company's struggle to maintain key technical support levels.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is currently under significant investor scrutiny as the market weighs high membership growth against persistent concerns regarding medical loss ratios and profitability ahead of its upcoming earnings report. The community remains deeply polarized, with bulls highlighting the stock's long-term valuation potential and institutional interest, while bears focus on recent insider selling patterns and the volatility of the healthcare insurance sector.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is currently trending as investors closely monitor executive management updates, ongoing litigation with X, and potential M&A speculation amid broader institutional interest in AI data infrastructure. Market participants are actively debating the stock's consolidation patterns ahead of upcoming earnings, with many focusing on the company's defensive positioning in defense and robotics sectors as a primary growth catalyst.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon shares are facing intense selling pressure as investors grapple with brand management concerns, ongoing CEO uncertainty, and reports of product quality issues. Despite the stock trading at valuation levels viewed by some as an attractive entry point, the community remains divided over whether to capitalize on the dip or brace for further downside amid the leadership vacuum.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is experiencing a surge in market activity driven by the growing demand for modular, off-grid power solutions in AI data centers, further fueled by a strategic partnership with Sustainable Development Capital LLP targeting 450 megawatts of capacity. While investors remain highly critical of past dilution and the lack of signed contracts, sentiment is shifting as market participants focus on the company's established carbon capture technology and its potential to alleviate energy infrastructure bottlenecks.

The Campbell's Co. engages in the business of manufacturing and marketing food and beverage products. It operates under the Meals and Beverages, and Snacks segments. The Meals and Beverages segment includes soup, meals, and beverage products in retail and foodservice. The Snacks segment offers cookies, crackers, bakery, and frozen products. The company was founded by Joseph Campbell and Abraham Anderson in 1869 and is headquartered in Camden, NJ.

Campbells Co (The)

Campbell Soup Co.

Campbell Soup is seeing intense volatility as investors weigh the impact of recent earnings misses, lowered forward guidance, and significant margin pressure from tariffs against the stock's valuation at multi-year lows. The community is sharply divided, with bulls pointing to iconic brands and defensive dividend yields as a value opportunity, while bears remain focused on high debt levels, supply chain headwinds, and shifting consumer sentiment toward processed food.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BridgeBio Oncology (BBOT) Spotlights Next-Gen RAS Pipeline, $425M Cash Runway Into 2028

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) used a presentation at Leerink Partners' Global Healthcare Conference to outline its strategy around next-generation RAS therapeutics, highlighting three...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Issues Quarterly Earnings Results

BridgeBio Oncology Therapeutics (NASDAQ:BBOT - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.49) EPS for the quarter, topping analysts' consensus...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Shares Gap Up After Better-Than-Expected Earnings

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Shares Gap Up Following Better-Than-Expected Earnings...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Price Target Raised to $29.00 at HC Wainwright

HC Wainwright lifted their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a "buy" rating in a report on Friday...

BridgeBio Oncology Touts Best in RAS Pipeline, Highlights BBO-8520 Response and Combo Tolerability

Executives from BridgeBio Oncology Therapeutics (NASDAQ:BBOT) outlined the company's strategy to build what they call the Best in RAS pipeline during an Oppenheimer-hosted discussion, emphasizing...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Shares Up 11.3% - Still a Buy?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading 11.3% Higher - What's Next...

Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.

BBOT
BridgeBio Oncology Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BBOT News

BBOTBridgeBio Oncology Therapeutics Inc.